Concepedia

Amy Flattery

AF

40

Publications

3.8K

Citations

29

H-Index

1994

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

MSD (Spain)

United States Military Academy

Amy Flattery is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and drug discovery.

Top concepts

Publications per year

1994–2022

40

Publications

40

Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical <i>Candida</i> sp. Isolates

S. Park, Rosemarie Kelly, Jennifer Nielsen Kahn et al. · Antimicrobial Agents and Chemotherapy · 2005 · 426 citations · Full text

, , +22

Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors

Cameron Douglas, Joseph A. D'Ippolito, G.-J. Shei et al. · Antimicrobial Agents and Chemotherapy · 1997 · 336 citations · Full text

, , +16

Discovery of Novel Antifungal (1,3)-β- <scp>d</scp> -Glucan Synthase Inhibitors

Janet C. Onishi, M. Meinz, John R. Thompson et al. · Antimicrobial Agents and Chemotherapy · 2000 · 313 citations · Full text

, , +15

In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)

K Bartizal, Christopher Gill, George K. Abruzzo et al. · Antimicrobial Agents and Chemotherapy · 1997 · 312 citations · Full text

, , +12

Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis

George K. Abruzzo, Amy Flattery, Christopher Gill et al. · Antimicrobial Agents and Chemotherapy · 1997 · 244 citations · Full text

Rows per page

1–5 of 40